AstraZeneca Gets FDA Approval for Breast Cancer Treatment
By Elias Schisgall
The Food and Drug Administration approved an AstraZeneca-made treatment for advanced breast cancer.
The agency on Friday said it granted accelerated approval for AstraZeneca's Etcamah drug, known generically as camizestrant, in combination with a CDK4/6 inhibitor to treat eligible breast cancer patients.
The approval applies to adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer, after detection of an estrogen receptor-1 mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy.
The FDA also approved a companion diagnostic test to detect emerging ESR1 resistance mutations, the company said.
"The Etcamah combination reflects AstraZeneca's leadership in redefining breast cancer care by pioneering a new approach using circulating tumour DNA and is the first and only medicine of its type in the 1st-line setting," AstraZeneca's executive vice president of the oncology haematology business unit, Dave Fredrickson said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
September 04, 2026 18:22 ET (22:22 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States